Labcorp Lifts FY Adjusted EPS Outlook to $18.30-$18.70
LH sits 35% above its 52-week low of $244.52.
Summary
Labcorp raised its full-year adjusted EPS guidance to $18.30-$18.70, up from the $18.10-$18.55 range it reaffirmed as recently as September 10, and now sees 2026 revenue of $14.78 billion to $14.89 billion, up 5.9%-6.7%. The midpoint of the EPS range moves up about 10 cents, a modest but real bump that implies management sees the second half tracking at or above plan. It comes after third-quarter revenue of $3.81 billion, net income of $262.8 million, EPS of $3.22 and adjusted EPS of $4.78, following a second quarter in which revenue of $3.73 billion and adjusted EPS of $4.99 beat consensus and the company lifted its outlook in July. The stock is trading near its 52-week high, so the raise reinforces rather than resets the story; the bigger swing factor remains the CMS 2027 lab reimbursement cuts flagged in September. Watch the pending BioReference asset deal (up to $872M) and the $210M Myriad prenatal acquisition for how the raised guidance absorbs integration costs.
At the time of this announcement, LH was trading at $330.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.9B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.